Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12:332–45. https://doi.org/10.2215/CJN.05000516.

Article  CAS  PubMed  Google Scholar 

Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9:265–70. https://doi.org/10.2215/CJN.04660513.

Article  PubMed  Google Scholar 

Yandian F, Caravaca-Fontán F, Herrera Hernandez LP, Soler MJ, Sethi S, Fervenza FC. Kidney diseases associated with inflammatory bowel disease: impact of chronic histologic damage, treatments, and outcomes. Kidney Int Rep. 2024;9:383–94. https://doi.org/10.1016/j.ekir.2023.11.011.

Article  PubMed  Google Scholar 

Adiga A, Goldfarb DS. The association of mesalamine with kidney disease. Adv Chronic Kidney Dis. 2020;27:72–6. https://doi.org/10.1053/j.ackd.2019.09.002.

Article  PubMed  Google Scholar 

Firwana BM, Hasan R, Chalhoub W, Ferwana M, Kang J-Y, Aron J, et al. Nephrotic syndrome after treatment of Crohn’s disease with mesalamine: case report and literature review. Avicenna J Med. 2012;2:9–11. https://doi.org/10.4103/2231-0770.94804.

Article  PubMed  PubMed Central  Google Scholar 

Ricciardi CA, Gnudi L. Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies. Metabolism. 2021;124:154890. https://doi.org/10.1016/j.metabol.2021.154890.

Article  CAS  PubMed  Google Scholar 

Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int J Mol Sci. 2021;22:623. https://doi.org/10.3390/ijms22020623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Y, Zhu Q, Yang X, Yan J, Shi J. Case of type 2 diabetes mellitus with edema resulting in subcutaneous insulin resistance syndrome. J Diabetes Investig. 2021;12:2267–70. https://doi.org/10.1111/jdi.13611.

Article  PubMed  PubMed Central  Google Scholar 

Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022;10:720–31. https://doi.org/10.1016/S2213-8587(22)00212-1.

Article  CAS  PubMed  Google Scholar 

Passanisi S, Salzano G, Bombaci B, Minuto N, Bassi M, Bonfanti R, et al. Sustained effectiveness of an advanced hybrid closed-loop system in a cohort of children and adolescents with type 1 diabetes: a 1-year real-world study. Diabetes Care. 2024;47:1084–91. https://doi.org/10.2337/dc23-2311.

Article  CAS  PubMed  Google Scholar 

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593–603. https://doi.org/10.2337/dci19-0028.

Article  PubMed  PubMed Central  Google Scholar 

Ravipati P, Reule S, Bren A, Bu L, Vaughn BP, Nachman PH. Kidney biopsy findings and clinical outcomes of US veterans with inflammatory bowel disease. Glomerular Dis. 2023;3:233–40. https://doi.org/10.1159/000534062.

Article  PubMed  PubMed Central  Google Scholar 

Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016;10:226–35. https://doi.org/10.1093/ecco-jcc/jjv138.

Article  PubMed  Google Scholar 

Wyant T, Eric F, Brihad A. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437–44. https://doi.org/10.1093/ecco-jcc/jjw092.

Article  PubMed  Google Scholar 

Nishizono R, Kogou H, Ishizaki Y, Minakawa A, Kikuchi M, Inagaki H, et al. Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report. BMC Nephrol. 2020;21:410. https://doi.org/10.1186/s12882-020-02071-6.

Article  PubMed  PubMed Central  Google Scholar 

Moyses Neto M, Silva GEB, Costa RS, Romão EA, Vieira Neto OM, Dantas M. Minimal change disease associated with type 1 and type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2012;56:331–5. https://doi.org/10.1590/S0004-27302012000500009.

Article  PubMed  Google Scholar 

Kwon AG, Sawaf H, Portalatin G, Shettigar S, Herlitz LC, Shafi T, et al. Kidney biopsy findings among patients with diabetes in the cleveland clinic kidney biopsy epidemiology project. Kidney Med. 2024;6:100889. https://doi.org/10.1016/j.xkme.2024.100889.

Article  PubMed  PubMed Central  Google Scholar 

Tsuyuki T, Kitamura M, Takatani M, Tsuji K, Torigoe K, Tsuji S, et al. Simultaneous presentation of minimal change disease and tubulointerstitial nephritis associated with primary Sjögren’s syndrome and Hashimoto’s thyroiditis. Intern Med. 2025;64:2361–8. https://doi.org/10.2169/internalmedicine.4747-24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmun Rev. 2019;18:549–55. https://doi.org/10.1016/j.autrev.2019.03.012.

Article  CAS  PubMed  Google Scholar 

Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, et al. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes. Pediatr Nephrol. 2013;28:1803–12. https://doi.org/10.1007/s00467-013-2498-4.

Article  PubMed  PubMed Central  Google Scholar 

Kim SH, Park SJ, Han KH, Kronbichler A, Saleem MA, Oh J, et al. Pathogenesis of minimal change nephrotic syndrome: an immunological concept. Korean J Pediatr. 2016;59:205–11. https://doi.org/10.3345/kjp.2016.59.5.205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roman M, Nowicki M. Detailed pathophysiology of minimal change disease: insights into podocyte dysfunction, immune dysregulation, and genetic susceptibility. Int J Mol Sci. 2024;25:12174. https://doi.org/10.3390/ijms252212174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curciarello R, Docena GH, MacDonald TT. The role of cytokines in the fibrotic responses in Crohn’s disease. Front Med (Lausanne). 2017;4:126. https://doi.org/10.3389/fmed.2017.00126.

Article  PubMed  PubMed Central  Google Scholar 

Chuang PY, Yu Q, Fang W, Uribarri J, He JC. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 2007;72:965–76. https://doi.org/10.1038/sj.ki.5002456.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barutta F, Bellini S, Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. Clin Sci (Lond). 2022;136:493–520. https://doi.org/10.1042/CS20210625.

Article  PubMed  PubMed Central  Google Scholar 

Dong Z, Wang Y, Qiu Q, Zhang X, Zhang L, Wu J, et al. Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients. Diabetes Res Clin Pract. 2016;121:112–8. https://doi.org/10.1016/j.diabres.2016.09.005.

Article  PubMed  Google Scholar 

Japanese Society of Nephrology. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol. 2024;28:473–95. https://doi.org/10.1007/s10157-024-02497-4.

Article  Google Scholar 

Shah P, Kalra S, Yadav Y, Deka N, Lathia T, Jacob JJ, et al. Management of glucocorticoid-induced hyperglycemia. Diabetes Metab Syndr Obes. 2022;15:1577–88. https://doi.org/10.2147/DMSO.S330253.

Article  CAS  PubMed  PubMed Central